Pharma Journalist -

Boehringer Ingelheim announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies…
Read More...

SMi Reports: New confirmed key speakers and updated agenda for Pharmaceutical Microbiology East Coast, with new dates due to the COVID-19 pandemic, the conference is now taking place on…
Read More...

There is no time like the present to share insights with peers on the new clinical trials being initiated to investigate JAK inhibitor use in patients with COVID-19. This critical…
Read More...

Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces SoteriaRx. This new platform of innovative on-dose technologies and…
Read More...

Recursion announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and…
Read More...

Neuraptive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the…
Read More...

Evonik announced the successful commissioning of an advanced biomaterials facility in Birmingham, USA that will support the increasing global market demand for the use of RESOMER…
Read More...

Catalent announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a…
Read More...

Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic…
Read More...

We are excited to release the digital event agenda for the Innate Immune Stimulating Therapies Summit, taking place on Wednesday, July 22. Download your copy here. Join the…
Read More...